Philippines - English - FDA (Food And Drug Administration)

verheilen pharm'l., inc. - cefixime (as trihydrate) - tablet - 100mg

Philippines - English - FDA (Food And Drug Administration)

verheilen pharm'l., inc. - cefixime (as trihydrate) - tablet, film coated - 200mg

Philippines - English - FDA (Food And Drug Administration)

j.m. tolmann labs inc - cefixime (as trihydrate) - granules for suspension (oral drops) - 20mg / ml

Philippines - English - FDA (Food And Drug Administration)

verheilen pharm'l., inc. - cefixime (as trihydrate) - tablet, film coated - 400mg

Philippines - English - FDA (Food And Drug Administration)

drugmaker's labs inc - cefixime (as trihydrate) - powder for suspension (oral drops) - 20mg / ml

Philippines - English - FDA (Food And Drug Administration)

aaa pharma, inc. - cefixime (as trihydrate) - tablet, film coated - 400mg

Philippines - English - FDA (Food And Drug Administration)

j.m. tolmann labs inc - cefixime (as trihydrate) - capsule - 200mg

Philippines - English - FDA (Food And Drug Administration)

watsons personal care stores (philippines), inc. - cefixime (as trihydrate) - capsule - 200 mg

United States - English - NLM (National Library of Medicine)

belcher pharmaceuticals,llc - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - to reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. in the absence of such data,local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months of age or older with the following infections when caused by susceptible isolates of the designated bacteria: uncomplicated urinary tract infections caused by escherichia coli and proteus mirabilis otitis media caused by haemophilus influenzae, moraxella catarrhalis, and streptococcus pyogenes. (efficacy for streptococcus py

United States - English - NLM (National Library of Medicine)

lupin pharma - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - cefixime anhydrous 100 mg - to reduce the development of drug resistant bacteria and maintain the effectiveness of suprax (cefixime) chewable tablets and other antibacterial drugs, suprax (cefixime) chewable tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. suprax (cefixime) chewable tablets are indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: uncomplicated urinary tract infections caused by escherichia coli and proteus mirabilis . otitis media caused by haemophilus influenzae (beta-lactamase positive and negative strains), moraxella (branhamella) catarrhalis , (most of which are beta-lactamase positive) and s. pyogene